IPP Bureau
Bengaluru’s STEERLife and Bionpharma secure USFDA nod for generic HIV drug
By IPP Bureau - January 14, 2026
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
US healthcare costs spark push for Ayurveda integration
By IPP Bureau - January 14, 2026
Thermo Fisher and NVIDIA team up to supercharge labs with AI
By IPP Bureau - January 14, 2026
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
BioMed X launches Harvard pilot to connect academia and pharma
By IPP Bureau - January 14, 2026
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
By IPP Bureau - January 14, 2026
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
GEA to power new biotechnology fermentation hub in Netherlands
By IPP Bureau - January 14, 2026
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
Metropolis Healthcare launches Genomics Centre to scale precision diagnostics and research
By IPP Bureau - January 14, 2026
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Firstsource acquires TeleMedik
By IPP Bureau - January 14, 2026
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Dr. Reddy’s launches first generic equivalent of extra-strength Pataday in US
By IPP Bureau - January 14, 2026
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery
By IPP Bureau - January 13, 2026
AbbVie strikes deal with Trump administration on drug prices, US investment
By IPP Bureau - January 13, 2026
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
By IPP Bureau - January 12, 2026
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer
By IPP Bureau - January 12, 2026
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Aragen slashes drug development time with CHOMax platform
By IPP Bureau - January 12, 2026
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy
By IPP Bureau - January 12, 2026
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
